What is Coya Therapeutics, Inc. Common Stock?
, a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs).
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 69.20M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.